Study #2017-0143
Phase II Study of Neoadjuvant Checkpoint Blockade in Patients with Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Ipilimumab
Description
This phase II trial studies how well nivolumab with and without ipilimumab and radiation therapy when given before surgery works in treating patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may work better in treating patients with undifferentiated pleomorphic sarcoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma
Study phase:
Phase II
Physician name:
Christina Roland
Department:
Surgical Oncology
For general questions about clinical trials:
1-866-397-2063
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.